- Email: [email protected]
Mann+Hummel inaugurates new China headquarters
NEWS/EXCHANGE RATES
Mann+Hummel inaugurates new China headquarters
A
utomotive filter manufacturer Mann+Hummel has officially opened its 60 000 sq m new China headquarters in Jiading after a E40 million investment. The new Jiading headquarters houses a 38 000 sq m manufacturing facility, a fully resourced R&D centre and a dedicated aftermarket warehouse. Completed on schedule earlier this year, the new plant will manufacture a range of products including air filter systems, air filter elements, oil and fuel filters, cabin air filters, intake manifold systems, crankcase ventilation systems and coolant reservoirs. The facility will mainly serve the growing Chinese market but a small percentage of output will be exported to other Mann+Hummel companies overseas. “This Jiading facility underscores the importance Mann+Hummel places on China, as well as in the region,” said Patrick Cudmore, group VP & CEO Mann+Hummel Asia-Pacific. “The Jiading facility takes Mann+Hummel closer to our goal of being one of the top automotive suppliers in China as we now have capabilities and facilities close to customers to meet their requirements. This integrated multi-functional state-of-the-art facility clearly puts Mann+Hummel in a strong position
to meet the needs of our customers in the future.” Mann+Hummel entered the Chinese market in 1996 and now has four companies in mainland China including three manufacturing companies in Changchun, Jinan and Shanghai.
Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Fax: +44 (0) 1865 843973 Web: www.filtrationindustryanalyst.com
For further information, visit www.mann-hummel.com
Editor: Roisin Reidy E-mail: [email protected]
Millipore shareholders approve takeover by Merck
Production Support Manager: Lin Lucas E-mail: [email protected]
M
illipore Corp’s shareholders have voted to approve the acquisition of Millipore by the German pharmaceutical and chemical company Merck KGaA (see Filtration Industry Analyst, March 2010). “The approval moves us another important step closer to officially becoming part of Merck KGaA,” said Martin Madaus, chairman, president and CEO of Millipore. “The proposed combination will position Millipore well for continued growth, offering greater global capabilities in R&D, manufacturing and customer service, while allowing us to maintain our headquarters in Billerica, Massachusetts.” Merck’s acquisition of Millipore is expected to close early in the third quarter of 2010.
For further information, visit www.millipore.com and www.merck.de
Exchange Rates against the US Dollar Date: 4.6.2010 Country Australia
Rate A$1.23
Country Netherlands
Rate E0.84
Austria
E0.84
Norway
Belgium
E0.84
Philippines
Canada
C$1.06
Singapore
Yn6.83
South Africa
R7.83
DKK6.23
South Korea
KWn1201.70
China Denmark
NOK6.66 Peso46.86 S$1.42
E0.84
Finland
E0.84
Spain
France
E0.84
Sweden
SEK8.08
E0.84
Switzerland
CHF1.16
Taiwan
T$32.45
Thailand
Bt32.67
Germany India Italy
Rs47.16 E0.84
Japan
¥91.65
UK
Malaysia
Rt3.33
USA
16
Filtration Industry Analyst
£0.69
Publisher: Greg Valero E-mail: [email protected]
Subscription Information An annual subscription to Filtration Industry Analyst includes 12 printed issues and online access for up to 5 users. Prices: 1120 for all European countries & Iran US$1256 for all countries except Europe and Japan ¥148 900 for Japan (Prices valid until 31 December 2010) To subscribe send payment to the address above. Tel: +44 (0)1865 843687/Fax: +44 (0)1865 834971 Email: [email protected], or via www.filtrationindustryanalyst.com. Subscriptions run for 12 months, from the date payment is received. Periodicals postage is paid at Rahway, NJ 07065, USA. Postmaster send all USA address corrections to: Filtration Industry Analyst, 365 Blair Road, Avenel, NJ 07001, USA Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/ or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Pre-press/Printed by Mayfield Press (Oxford) LImited 02207
US$1.00
June 2010
Mann+Hummel inaugurates new China headquarters
A
utomotive filter manufacturer Mann+Hummel has officially opened its 60 000 sq m new China headquarters in Jiading after a E40 million investment. The new Jiading headquarters houses a 38 000 sq m manufacturing facility, a fully resourced R&D centre and a dedicated aftermarket warehouse. Completed on schedule earlier this year, the new plant will manufacture a range of products including air filter systems, air filter elements, oil and fuel filters, cabin air filters, intake manifold systems, crankcase ventilation systems and coolant reservoirs. The facility will mainly serve the growing Chinese market but a small percentage of output will be exported to other Mann+Hummel companies overseas. “This Jiading facility underscores the importance Mann+Hummel places on China, as well as in the region,” said Patrick Cudmore, group VP & CEO Mann+Hummel Asia-Pacific. “The Jiading facility takes Mann+Hummel closer to our goal of being one of the top automotive suppliers in China as we now have capabilities and facilities close to customers to meet their requirements. This integrated multi-functional state-of-the-art facility clearly puts Mann+Hummel in a strong position
to meet the needs of our customers in the future.” Mann+Hummel entered the Chinese market in 1996 and now has four companies in mainland China including three manufacturing companies in Changchun, Jinan and Shanghai.
Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Fax: +44 (0) 1865 843973 Web: www.filtrationindustryanalyst.com
For further information, visit www.mann-hummel.com
Editor: Roisin Reidy E-mail: [email protected]
Millipore shareholders approve takeover by Merck
Production Support Manager: Lin Lucas E-mail: [email protected]
M
illipore Corp’s shareholders have voted to approve the acquisition of Millipore by the German pharmaceutical and chemical company Merck KGaA (see Filtration Industry Analyst, March 2010). “The approval moves us another important step closer to officially becoming part of Merck KGaA,” said Martin Madaus, chairman, president and CEO of Millipore. “The proposed combination will position Millipore well for continued growth, offering greater global capabilities in R&D, manufacturing and customer service, while allowing us to maintain our headquarters in Billerica, Massachusetts.” Merck’s acquisition of Millipore is expected to close early in the third quarter of 2010.
For further information, visit www.millipore.com and www.merck.de
Exchange Rates against the US Dollar Date: 4.6.2010 Country Australia
Rate A$1.23
Country Netherlands
Rate E0.84
Austria
E0.84
Norway
Belgium
E0.84
Philippines
Canada
C$1.06
Singapore
Yn6.83
South Africa
R7.83
DKK6.23
South Korea
KWn1201.70
China Denmark
NOK6.66 Peso46.86 S$1.42
E0.84
Finland
E0.84
Spain
France
E0.84
Sweden
SEK8.08
E0.84
Switzerland
CHF1.16
Taiwan
T$32.45
Thailand
Bt32.67
Germany India Italy
Rs47.16 E0.84
Japan
¥91.65
UK
Malaysia
Rt3.33
USA
16
Filtration Industry Analyst
£0.69
Publisher: Greg Valero E-mail: [email protected]
Subscription Information An annual subscription to Filtration Industry Analyst includes 12 printed issues and online access for up to 5 users. Prices: 1120 for all European countries & Iran US$1256 for all countries except Europe and Japan ¥148 900 for Japan (Prices valid until 31 December 2010) To subscribe send payment to the address above. Tel: +44 (0)1865 843687/Fax: +44 (0)1865 834971 Email: [email protected], or via www.filtrationindustryanalyst.com. Subscriptions run for 12 months, from the date payment is received. Periodicals postage is paid at Rahway, NJ 07065, USA. Postmaster send all USA address corrections to: Filtration Industry Analyst, 365 Blair Road, Avenel, NJ 07001, USA Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/ or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Pre-press/Printed by Mayfield Press (Oxford) LImited 02207
US$1.00
June 2010